Summit Therapeutics Files 8-K with Financials
Ticker: SMMT · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-statements, regulatory-filing
TL;DR
Summit Therapeutics filed an 8-K, mostly financials. No major news.
AI Summary
Summit Therapeutics Inc. filed an 8-K on September 8, 2025, reporting on events that occurred on September 7, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates routine corporate reporting, likely containing updated financial statements and exhibits for regulatory purposes.
Risk Assessment
Risk Level: low — The filing appears to be routine financial reporting and does not disclose any significant new risks or material events.
Key Numbers
- 001-36866 — Commission File Number (Identifies the company's SEC filing history.)
- 37-1979717 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- September 7, 2025 (date) — Earliest Event Reported
- September 8, 2025 (date) — Date of Report
- 601 Brickell Key Drive, Suite 1000, Miami, FL 33131 (address) — Principal Executive Offices
FAQ
What specific financial statements or exhibits are included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but the specific details are not provided in the excerpt.
What is the exact date of the earliest event reported in this filing?
The earliest event reported is September 7, 2025.
What is the principal executive office address for Summit Therapeutics Inc.?
The principal executive office is located at 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
What is the Commission File Number for Summit Therapeutics Inc.?
The Commission File Number is 001-36866.
Has Summit Therapeutics Inc. had previous names or addresses reported to the SEC?
Yes, the filing notes former names 'Summit Therapeutics plc' and 'Summit Corp plc' with dates of name changes in 2015 and 2014, respectively.
Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-09-08 07:45:14
Key Financial Figures
- $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
Filing Documents
- smmt-20250907.htm (8-K) — 29KB
- a2025_prx0907xwclcharmon.htm (EX-99.1) — 21KB
- a20250905wclcupdatecallp.htm (EX-99.2) — 35KB
- a20250905wclcupdatecallp001.jpg (GRAPHIC) — 43KB
- a20250905wclcupdatecallp002.jpg (GRAPHIC) — 306KB
- a20250905wclcupdatecallp003.jpg (GRAPHIC) — 147KB
- a20250905wclcupdatecallp004.jpg (GRAPHIC) — 140KB
- a20250905wclcupdatecallp005.jpg (GRAPHIC) — 127KB
- a20250905wclcupdatecallp006.jpg (GRAPHIC) — 140KB
- a20250905wclcupdatecallp007.jpg (GRAPHIC) — 142KB
- a20250905wclcupdatecallp008.jpg (GRAPHIC) — 111KB
- a20250905wclcupdatecallp009.jpg (GRAPHIC) — 126KB
- a20250905wclcupdatecallp010.jpg (GRAPHIC) — 103KB
- a20250905wclcupdatecallp011.jpg (GRAPHIC) — 129KB
- a20250905wclcupdatecallp012.jpg (GRAPHIC) — 117KB
- a20250905wclcupdatecallp013.jpg (GRAPHIC) — 126KB
- a20250905wclcupdatecallp014.jpg (GRAPHIC) — 133KB
- a20250905wclcupdatecallp015.jpg (GRAPHIC) — 131KB
- a20250905wclcupdatecallp016.jpg (GRAPHIC) — 79KB
- a20250905wclcupdatecallp017.jpg (GRAPHIC) — 132KB
- a20250905wclcupdatecallp018.jpg (GRAPHIC) — 124KB
- a20250905wclcupdatecallp019.jpg (GRAPHIC) — 127KB
- a20250905wclcupdatecallp020.jpg (GRAPHIC) — 96KB
- a20250905wclcupdatecallp021.jpg (GRAPHIC) — 31KB
- a2025_prx0907xwclcharmon001.jpg (GRAPHIC) — 234KB
- a2025_prx0907xwclcharmon002.jpg (GRAPHIC) — 242KB
- a2025_prx0907xwclcharmon003.jpg (GRAPHIC) — 236KB
- a2025_prx0907xwclcharmon004.jpg (GRAPHIC) — 250KB
- a2025_prx0907xwclcharmon005.jpg (GRAPHIC) — 212KB
- a2025_prx0907xwclcharmon006.jpg (GRAPHIC) — 235KB
- 0001599298-25-000137.txt ( ) — 5785KB
- smmt-20250907.xsd (EX-101.SCH) — 2KB
- smmt-20250907_def.xml (EX-101.DEF) — 14KB
- smmt-20250907_lab.xml (EX-101.LAB) — 25KB
- smmt-20250907_pre.xml (EX-101.PRE) — 15KB
- smmt-20250907_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On September 7, 2025, Summit Therapeutics Inc. (the "Company") issued a press release announcing the ivonescimab data relating to its global Phase III clinical trial, HARMONi. The data was presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer's 2025 World Conference on Lung Cancer by Jonathan Goldman, MD, Professor of Medicine at UCLA in the Hematology/Oncology Division, UCLA Director of Clinical Trials in Thoracic Oncology, Associate Director of Early Drug Development, and Chair of University of California Lung Cancer Consortium on September 7, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The Company will utilize slides during its conference call scheduled for 8:00am ET on September 8, 2025, discussing the ivonescimab data from HARMONi. A copy of the slides is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release, dated September 7, 2025 99.2 Presentation Slides for September 8, 2025 Conference Call 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: September 8, 2025 By: /s/ Manmeet S. Soni Chief Operating Officer, Chief Financial Officer and Director (Principal Financial Officer)